A Phase 2 interventional study of Fuke Qianjin capsule and Placebo oral capsule in Chronic Pelvic Pain, sponsored by Aijun Sun. Status unknown at 1 site in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-02-05.
Sponsored by Aijun Sun · Phase 2, Interventional, and Treatment
Among 14 studies in Pelvic Pain with a site in China — 5 open to participants now, 5 under way, 1 of them phase 3. Pelvic Pain · China.
Among the 14 studies in Pelvic Pain with a site in China, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2016, is one of 2 in phase 2, and was the 1st registered.
376 studies on the registry are indexed under Pelvic Pain; 90 are open to participants now.
Browse Pelvic Pain studies →5 of the 14 studies in Pelvic Pain with a site in China are open now. Recruiting first, the newest first:
Li Li · Sites in China
Ages 18–45 · Women only · Healthy volunteers
Peking Union Medical College Hospital · Sites in China
Ages 18–45 · Women only · Healthy volunteers
Peking University Third Hospital · Sites in China
Ages 18–35 · Women only
Beijing Konruns Pharmaceutical Co., Ltd. · Sites in China
Ages 18–50 · Women only
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–45 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 60 Pelvic Pain studies recruiting now, 22 (37%) set no upper age limit and 36 (60%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 60 across 278 interventional studies indexed under Pelvic Pain.
Median enrollment 198 across the 12 interventional studies, 359 across the 2 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 14 have an industry lead sponsor. The 10 most frequent:
Aijun Sun is the lead sponsor of 2 studies on the registry; none are open to participants now.
Aijun Sun has 1 study filed under Pelvic Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Pelvic Pain with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A prospective random control clinical trials to research Fuke Qianjin capsule's effects on ameliorating the pain caused by chronic pelvic disease.
Fuke Qianjin capsule has been widely used in clinical medicine to ameliorate the pain caused by chronic pelvic disease.But random control trials on its effects are few.Our study was designed as a prospective random control clinical trials to research its effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fuke Qianjin capsule, 2 pills each time,three times a day, orally (0.4g/pill）,for 2months,
Drug: Fuke Qianjin capsule
placebo pills, 2 pills each time,three times a day, orally, for 2months
Drug: Placebo oral capsule
Fuke Qianjin capsule 0.8g pills by mouth, three times daily
Placebo oral capsule 0.8g pill by mouth, three times daily
Visual Analogue Scale Score(VAS score) of pelvic pain
pelvic pain degree related assessment
Time frame: 5 minutes
C-reaction protein(CRP)
inflammation response biomarker assessment
Time frame: 5 minutes
Interleukin 6 (IL-6)
pro-inflammatory cytokine assessment
Time frame: 5 minutes
Tumor necrosis factor alpha (TNFα)
systemic inflammation biomarker assessment
Time frame: 5 minutes
The Short Form (36) Health Survey (SF-36)
health status measure
Time frame: 5 minutes
Short-form McGill Pain Questionnaire (SF-MPQ)
pain assessment
Time frame: 5 minutes
Plan to share: Yes — Network platform, and the website will be attached later.
Supporting information: Study protocol, Informed consent form, Clinical study report, Analytic code
Time frame: Within 2 months after the trial complete
Access criteria: Data access requests will be reviewed by an external independent review panel.Requestors will be required to sign a Data Access Agreement.
Ran from Dec 2016 to primary completion in Dec 2017, 12 months.
Of 14 phase 2 interventional studies under Pelvic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 29. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aijun Sun